AUROPHARMAAurobindo Pharma Limited
Pharma · Drug Manufacturers - Specialty & Generic · NSE · as of 2026-10-26 (delayed ~30 min in market hours)
Aurobindo Pharma Limited, a biopharmaceutical company, develops, manufactures, commercializes, and sells generic pharmaceuticals, active pharmaceutical ingredients (APIs), and injectables. The company offers formulation in form of oral solids, liquids, injectables, vaccines, and metered dose inhalers; and APIs, biosimilars, and peptides targeting therapeutic areas, such as central nervous system, cardiovascular, respiratory, antibiotics, anti-retroviral, anti-diabetics, gastroenterology, oncology, and dermatology. It also provides antiretroviral drugs for the people and children living with HIV; and API space for sterile and non-sterile penicillin's, cephalosporins, penems, and non-beta lactams. The company has operations in India, the United States, Europe, Puerto Rico, and internationally. The company was incorporated in 1986 and is headquartered in Hyderabad, India.
Price & Volume
Loading chart…
Key Ratios
“—” means the figure isn't meaningful or isn't published for this company: ROE and Debt/Equity are undefined when shareholder equity is negative (check P/B — negative means negative equity), and DII/MF holding splits aren't provided by our current data source.
Active Pattern Signals
None of the 16 pattern scanners currently detects a setup on AUROPHARMA — signals appear here automatically when one forms (checked on every data refresh). The Trade Plan on the right always provides stop-loss and target levels regardless.
The picture
- • Debt/Equity: 0.21
- • Promoter holding: 54.8%
- • Valuation vs sector: P/E 26.6 vs sector 35.5
- • Price vs SMA200: above
- • Golden cross setup: SMA50 above SMA200
- • 3-month vs NIFTY: +6.9% relative
Bull case
- • Debt/Equity: 0.21
- • Promoter holding: 54.8%
- • Valuation vs sector: P/E 26.6 vs sector 35.5
- • Price vs SMA200: above
Bear case
- • Revenue growth: 5.6% YoY
- • Profit growth: 1.9% YoY
- • RSI: 40
- • MACD: bearish
Key risks
- • Weak fundamentals — technical strength may not sustain
- • Revenue growth: 5.6% YoY
- • Profit growth: 1.9% YoY
Algorithmic analysis for research only — not SEBI-registered investment advice.
Trade Plan
Stop = 20-day support with a 2.5×ATR risk cap (ATR ₹42.97). Levels recompute on every data refresh. Position sizing and execution are yours — this is analysis, not advice.